Inflection Biosciences Ltd is an early stage, drug development company with a focus on discovering and developing innovative small molecule therapeutics addressing major unmet needs in cancer. Based in Dublin and Boston, Inflection Biosciences’ strategy is to find and license the best drug discovery projects from around the world and to progress them through pre-clinical and early clinical stages before seeking partners for later-stage clinical development and commercialisation.
Inflection Biosciences evaluates potential licensing candidates using the strictest criteria based on technical feasibility and commercial viability to ensure that chosen projects have the maximum likelihood of reaching development clinical milestones.
We are committed to a rational, data-driven evidence-based approach for final candidate selection. Licensing candidates are subjected to a rigorous testing regime to validate previous work and to identify essential differentiating factors against other early-stage projects.